European Guideline on IgG4-related digestive disease - UEG and SGF evidence-based recommendations

Basit Öğe Kaydı
dc.contributor.authorLohr, J-Matthias
dc.contributor.authorBeuers, Ulrich
dc.contributor.authorVujasinovic, Miroslav
dc.contributor.authorAlvaro, Domenico
dc.contributor.authorFrokjaer, Jens Brondum
dc.contributor.authorButtgereit, Frank
dc.contributor.authorCapurso, Gabriele
dc.date.accessioned2021-01-14T18:10:33Z
dc.date.available2021-01-14T18:10:33Z
dc.date.issued2020
dc.departmentKKÜ
dc.descriptionFrulloni, Luca/0000-0001-7417-2655; Hart, Phil/0000-0003-4346-6196; Capurso, Gabriele/0000-0002-0019-8753; de-Madaria, Enrique/0000-0002-2412-9541; Lohr, Matthias/0000-0002-7647-198X; Frokjaer, Jens Brondum/0000-0001-8722-0070
dc.description.abstractThe overall objective of these guidelines is to provide evidence-based recommendations for the diagnosis and management of immunoglobulin G4 (IgG4)-related digestive disease in adults and children. IgG4-related digestive disease can be diagnosed only with a comprehensive work-up that includes histology, organ morphology at imaging, serology, search for other organ involvement, and response to glucocorticoid treatment. Indications for treatment are symptomatic patients with obstructive jaundice, abdominal pain, posterior pancreatic pain, and involvement of extra-pancreatic digestive organs, including IgG4-related cholangitis. Treatment with glucocorticoids should be weight-based and initiated at a dose of 0.6-0.8 mg/kg body weight/day orally (typical starting dose 30-40 mg/day prednisone equivalent) for 1 month to induce remission and then be tapered within two additional months. Response to initial treatment should be assessed at week 2-4 with clinical, biochemical and morphological markers. Maintenance treatment with glucocorticoids should be considered in multi-organ disease or history of relapse. If there is no change in disease activity and burden within 3 months, the diagnosis should be reconsidered. If the disease relapsed during the 3 months of treatment, immunosuppressive drugs should be added.en_US
dc.description.sponsorshipNational Societies Committee of the United European Gastroenterology (UEG)en_US
dc.description.sponsorshipWe gratefully acknowledge the support from the National Societies Committee of the United European Gastroenterology (UEG) for the conduct of these guidelines independent from other sources. No other funding was received.en_US
dc.identifier.citationLöhr, J.-M., Beuers, U., Vujasinovic, M., Alvaro, D., Frøkjær, J.B., Buttgereit, F., Capurso, G., Culver, E.L., de-Madaria, E., Della-Torre, E., Detlefsen, S., Dominguez-Muñoz, E., Czubkowski, P., Ewald, N., Frulloni, L., Gubergrits, N., Duman, D.G., Hackert, T., Iglesias-Garcia, J., Kartalis, N., Laghi, A., Lammert, F., Lindgren, F., Okhlobystin, A., Oracz, G., Parniczky, A., Mucelli, R.M.P., Rebours, V., Rosendahl, J., Schleinitz, N., Schneider, A., van Bommel, E.F., Verbeke, C.S., Vullierme, M.P., Witt, H. and (2020), European Guideline on IgG4-related digestive disease – UEG and SGF evidence-based recommendations. UEG Journal, 8(6), 637-666.en_US
dc.identifier.doi10.1177/2050640620934911
dc.identifier.endpage666en_US
dc.identifier.issn2050-6406
dc.identifier.issn2050-6414
dc.identifier.issue6en_US
dc.identifier.pmid32552502
dc.identifier.scopus2-s2.0-85086576981
dc.identifier.scopusqualityQ1
dc.identifier.startpage637en_US
dc.identifier.urihttps://doi.org/10.1177/2050640620934911
dc.identifier.urihttps://hdl.handle.net/20.500.12587/12666
dc.identifier.volume8en_US
dc.identifier.wosWOS:000542363500001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSAGE PUBLICATIONS INCen_US
dc.relation.ispartofUNITED EUROPEAN GASTROENTEROLOGY JOURNAL
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectIgG4-relateden_US
dc.subjectdigestiveen_US
dc.subjectdiseaseen_US
dc.subjectglucocorticoidsen_US
dc.subjectother organ involvementen_US
dc.subjectbiomarkersen_US
dc.subjectautoimmune pancreatitis type 1en_US
dc.subjectimmune-related cholangitisen_US
dc.subjectcanceren_US
dc.subjectdiabetes mellitusen_US
dc.titleEuropean Guideline on IgG4-related digestive disease - UEG and SGF evidence-based recommendationsen_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
European Guideline on IgG4‐related digestive disease UEG and SGF evidence‐based.pdf
Boyut:
1.15 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu